284 related articles for article (PubMed ID: 8687151)
61. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial.
Schink M; Tröger W; Dabidian A; Goyert A; Scheuerecker H; Meyer J; Fischer IU; Glaser F
Forsch Komplementmed; 2007 Feb; 14(1):9-17. PubMed ID: 17341882
[TBL] [Abstract][Full Text] [Related]
62. [Mistletoe in the treatment of cancer].
Bruseth S; Enge A
Tidsskr Nor Laegeforen; 1993 Mar; 113(9):1058-60. PubMed ID: 8493669
[TBL] [Abstract][Full Text] [Related]
63. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts.
Rostock M; Huber R; Greiner T; Fritz P; Scheer R; Schueler J; Fiebig HH
Anticancer Res; 2005; 25(3B):1969-75. PubMed ID: 16158932
[TBL] [Abstract][Full Text] [Related]
64. [Oncologic mistletoe therapy: physicians' use and estimation of efficiency].
Münstedt K; Entezami A; Kullmer U
Dtsch Med Wochenschr; 2000 Oct; 125(41):1222-6. PubMed ID: 11076260
[TBL] [Abstract][Full Text] [Related]
65. Therapeutic effects of HESA-A in patients with end-stage metastatic cancers.
Ahmadi A; Mohagheghi M; Karimi M; Golestanha SA; Naseri M; Faghihzadeh S; Habibi G
Integr Cancer Ther; 2010 Mar; 9(1):32-5. PubMed ID: 20150223
[TBL] [Abstract][Full Text] [Related]
66. [Use of alternative medicine in oncology patients].
Grothey A; Düppe J; Hasenburg A; Voigtmann R
Dtsch Med Wochenschr; 1998 Jul; 123(31-32):923-9. PubMed ID: 9721567
[TBL] [Abstract][Full Text] [Related]
67. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
[TBL] [Abstract][Full Text] [Related]
68. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.
Friess H; Büchler M; Beglinger C; Weber A; Kunz J; Fritsch K; Dennler HJ; Beger HG
Pancreas; 1993 Sep; 8(5):540-5. PubMed ID: 8302789
[TBL] [Abstract][Full Text] [Related]
69. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
[TBL] [Abstract][Full Text] [Related]
70. [Anthroposophy. Mistletoe preparations: a cancer inhibiting wonder drug?].
Arm F
Krankenpfl Soins Infirm; 1989 May; 82(5):18-21. PubMed ID: 2747189
[No Abstract] [Full Text] [Related]
71. [Possibilities and limits of mistletoe therapy in cancer patients].
Hoffmann J
Arch Gynecol Obstet; 1987; 242(1-4):257-60. PubMed ID: 3688952
[No Abstract] [Full Text] [Related]
72. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL).
Wode K; Hök Nordberg J; Kienle GS; Elander NO; Bernhardson BM; Sunde B; Sharp L; Henriksson R; Fransson P
Trials; 2020 Sep; 21(1):783. PubMed ID: 32917288
[TBL] [Abstract][Full Text] [Related]
73. Differences in the in vitro effectiveness of preparations produced from mistletoes of various host trees.
Hülsen H; Doser C; Mechelke F
Arzneimittelforschung; 1986 Mar; 36(3):433-6. PubMed ID: 3707661
[TBL] [Abstract][Full Text] [Related]
74. The case for mistletoe in the treatment of laryngeal cancer.
Shakeel M; Trinidade A; Geider S; Ah-See KW
J Laryngol Otol; 2014 Mar; 128(3):302-6. PubMed ID: 24548675
[TBL] [Abstract][Full Text] [Related]
75. [Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts].
Schink M; Tröger W; Goyert A; Scheuerecker H; Selbmann HK; Glaser F
Forsch Komplementmed; 2006 Jun; 13(3):147-55. PubMed ID: 16868360
[TBL] [Abstract][Full Text] [Related]
76. Apparent response of small cell lung cancer to an extract of mistletoe and homoeopathic treatment.
Bradley GW; Clover A
Thorax; 1989 Dec; 44(12):1047-8. PubMed ID: 2559483
[TBL] [Abstract][Full Text] [Related]
77. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.).
Hutt N; Kopferschmitt-Kubler M; Cabalion J; Purohit A; Alt M; Pauli G
Allergol Immunopathol (Madr); 2001; 29(5):201-3. PubMed ID: 11720654
[TBL] [Abstract][Full Text] [Related]
78. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
79. [Iscador--mistletoe extract for cancer treatment. Documentation No. 10].
Schweiz Rundsch Med Prax; 1988 Jan; 77(4):69-74. PubMed ID: 3279479
[No Abstract] [Full Text] [Related]
80. [Studies on additional Iscador therapy in the management of women with surgically and radiotherapeutically treated genital carcinoma].
Leroi R
Gynaecologia; 1969; 167(3):158-70. PubMed ID: 4305038
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
